Other current hypoglycemic drugs lack evidence of their effect on liver fibrosis and are not considered drugs for T2D patients with MASLD
Babaei A, Pourmotabbed A, Talebi S, et al
Studies have found that the activation of GIP, when combined with GLP-1 receptor activation, leads to more substantial weight loss in mice compared to the use of either agent on its own
Alternative repletion strategies have focused on oral administration of GSH precursors (e.g., cysteine and glycine supplementation 9 ), and intravenous administration of GSH, 10 which although promising, is invasive and inconvenient, and therefore unlikely to be a practical solution
Not only do you risk infection from needles, but its challenging to know youll react to the pure compound delivered directly into your bloodstream
doi: 10.1016/j.pnpbp.2020.109939 6 AndradeC